SEC Filing Summary: AspenBio Pharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on October 15, 2009. The filing serves as a Regulation FD disclosure to distribute a shareholder letter titled "AspenBio Pharma Progress Update" and an accompanying PowerPoint presentation. The company is incorporated in Colorado and maintains its principal executive offices in Castle Rock, Colorado.
Note: The request metadata referenced "Riot Platforms, Inc.", but the provided filing text explicitly identifies the registrant as "AspenBio Pharma, Inc."
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts solely as a cover for the distribution of a progress update letter and presentation, which are attached as exhibits.
Material Changes
No material financial changes or comparative period data are detailed within the text of this Form 8-K. The filing references a webcast and presentation for further details on company progress.
Guidance, Outlook, and Risks
Management commentary is contained within the attached Exhibit 99.1 (Shareholder Letter) and Exhibit 99.2 (PowerPoint Presentation). The filing itself does not contain specific guidance, risk factors, or descriptions of unusual items.
Key Facts for Investor Verification
- Verify the contents of the "AspenBio Pharma Progress Update" letter (Exhibit 99.1) for specific operational milestones.
- Review the PowerPoint presentation (Exhibit 99.2) for financial data and strategic outlook not included in the 8-K text.
- Confirm the discrepancy between the requested company name (Riot Platforms) and the actual filing registrant (AspenBio Pharma).
- Check the company website for the referenced webcast and presentation materials.